Moderna, Inc. Payments to Acquire Debt Securities, Available-for-sale
Moderna, Inc. (MRNA) reported Payments to Acquire Debt Securities, Available-for-sale of $1.90 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-07-31
- Moderna, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $556.00M, a 57.07% decline year-over-year.
- Moderna, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $1.35B, a 23.58% decline year-over-year.
- Moderna, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $1.55B, a 18.06% decline year-over-year.
- Moderna, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $1.16B, a 7.11% decline year-over-year.
- Moderna, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $5.77B, a 11.66% decline from fiscal 2024.
- Moderna, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $6.53B, a 73.64% increase from fiscal 2023.
- Moderna, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $3.76B, a 67.12% decline from fiscal 2022.
- Moderna, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $11.44B, a 9.62% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 3 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 6 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 9 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 12 month | Payments to Acquire Debt Securities, Available-for-sale 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $556.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $1.90B 10-Q · filed 2026-07-31 | $3.45B derived: sum of 3 quarters · filed 2026-07-31 | $4.61B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | $1.35B 10-Q · filed 2026-05-01 | $2.90B derived: sum of 2 quarters · filed 2026-05-01 | $4.06B derived: sum of 3 quarters · filed 2026-05-01 | $5.35B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | $1.55B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $2.71B derived: sum of 2 quarters · filed 2026-02-20 | $4.00B derived: sum of 3 quarters · filed 2026-07-31 | $5.77B 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | $1.16B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.46B derived: sum of 2 quarters · filed 2026-07-31 | $4.22B 10-Q · filed 2025-11-06 | $6.11B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | $1.29B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $3.06B 10-Q · filed 2026-07-31 | $4.95B derived: sum of 3 quarters · filed 2026-07-31 | $6.20B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | $1.76B 10-Q · filed 2026-05-01 | $3.65B derived: sum of 2 quarters · filed 2026-05-01 | $4.90B derived: sum of 3 quarters · filed 2026-05-01 | $5.75B derived: sum of 4 quarters · filed 2026-05-01 | ||||
| 2024-12-31 | $1.89B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $3.14B derived: sum of 2 quarters · filed 2026-02-20 | $3.98B derived: sum of 3 quarters · filed 2026-02-20 | $6.53B 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | $1.25B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.10B derived: sum of 2 quarters · filed 2025-11-06 | $4.64B 10-Q · filed 2025-11-06 | $6.30B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | $846.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $3.39B 10-Q · filed 2025-08-01 | $5.05B derived: sum of 3 quarters · filed 2026-02-20 | $5.87B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | $2.54B 10-Q · filed 2025-05-01 | $4.21B derived: sum of 2 quarters · filed 2026-02-20 | $5.02B derived: sum of 3 quarters · filed 2026-02-20 | $5.22B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | $1.66B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $2.48B derived: sum of 2 quarters · filed 2026-02-20 | $2.67B derived: sum of 3 quarters · filed 2026-02-20 | $3.76B 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | $816.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.01B derived: sum of 2 quarters · filed 2024-11-07 | $2.10B 10-Q · filed 2024-11-07 | $4.61B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-06-30 | $196.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $1.28B 10-Q · filed 2024-08-01 | $3.79B derived: sum of 3 quarters · filed 2025-02-21 | $3.98B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-03-31 | $1.08B 10-Q · filed 2024-05-02 | $3.60B derived: sum of 2 quarters · filed 2025-02-21 | $3.79B derived: sum of 3 quarters · filed 2025-02-21 | $6.95B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2022-12-31 | $2.51B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $2.70B derived: sum of 2 quarters · filed 2025-02-21 | $5.86B derived: sum of 3 quarters · filed 2025-02-21 | $11.44B 10-K · filed 2025-02-21 | ||||
| 2022-09-30 | $191.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $3.35B derived: sum of 2 quarters · filed 2023-11-03 | $8.93B 10-Q · filed 2023-11-03 | $11.30B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-06-30 | $3.16B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $8.73B 10-Q · filed 2023-08-03 | $11.11B derived: sum of 3 quarters · filed 2024-02-23 | $14.83B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-03-31 | $5.57B 10-Q · filed 2023-05-04 | $7.95B derived: sum of 2 quarters · filed 2024-02-23 | $11.66B derived: sum of 3 quarters · filed 2024-02-23 | $17.50B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2021-12-31 | $2.37B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $6.09B derived: sum of 2 quarters · filed 2024-02-23 | $11.93B derived: sum of 3 quarters · filed 2024-02-23 | $12.65B 10-K · filed 2024-02-23 | ||||
| 2021-09-30 | $3.72B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $9.55B derived: sum of 2 quarters · filed 2022-11-03 | $10.28B 10-Q · filed 2022-11-03 | $10.91B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-06-30 | $5.83B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $6.56B 10-Q · filed 2022-08-03 | $7.19B derived: sum of 3 quarters · filed 2023-02-24 | $8.61B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-03-31 | $726.00M 10-Q · filed 2022-05-04 | $1.36B derived: sum of 2 quarters · filed 2023-02-24 | $2.78B derived: sum of 3 quarters · filed 2023-02-24 | $3.06B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2020-12-31 | $630.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $2.05B derived: sum of 2 quarters · filed 2023-02-24 | $2.33B derived: sum of 3 quarters · filed 2023-02-24 | $2.96B 10-K · filed 2023-02-24 | $2.96B 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $1.42B derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $1.71B derived: sum of 2 quarters · filed 2021-11-04 | $2.33B 10-Q · filed 2021-11-04 | $2.33B 10-Q · filed 2020-10-30 | $2.52B derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-06-30 | $282.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $903.00M 10-Q · filed 2021-08-05 | $903.61M 10-Q · filed 2020-08-06 | $1.10B derived: sum of 3 quarters · filed 2022-02-25 | $1.20B derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-03-31 | $621.00M 10-Q · filed 2021-05-06 | $621.26M 10-Q · filed 2020-05-07 | $816.72M derived: sum of 2 quarters · filed 2022-02-25 | $922.69M derived: sum of 3 quarters · filed 2022-02-25 | $1.34B derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2019-12-31 | $195.72M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $301.69M derived: sum of 2 quarters · filed 2022-02-25 | $715.48M derived: sum of 3 quarters · filed 2022-02-25 | $1.15B 10-K · filed 2022-02-25 | $1.15B 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $105.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $519.76M derived: sum of 2 quarters · filed 2020-10-30 | $949.28M 10-Q · filed 2020-10-30 | $1.23B derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-06-30 | $413.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $843.31M 10-Q · filed 2020-08-06 | $1.12B derived: sum of 3 quarters · filed 2021-02-26 | $1.23B derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-03-31 | $429.52M 10-Q · filed 2020-05-07 | $706.03M derived: sum of 2 quarters · filed 2021-02-26 | $819.24M derived: sum of 3 quarters · filed 2021-02-26 | $996.99M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2018-12-31 | $276.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $389.73M derived: sum of 2 quarters · filed 2021-02-26 | $567.47M derived: sum of 3 quarters · filed 2021-02-26 | $1.23B 10-K · filed 2021-02-26 | ||||
| 2018-09-30 | $113.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $290.95M derived: sum of 2 quarters · filed 2019-11-06 | $951.19M 10-Q · filed 2019-11-06 | |||||
| 2018-06-30 | $177.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $837.98M 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | $660.24M 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | $727.20M 10-K · filed 2020-02-27 | |||||||
| 2016-12-31 | $1.42B 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |